Dérivés de benzopyrrolidinone, leur procédé de préparation et les compositions pharmaceutiques les renfermant
申请人:ADIR ET COMPAGNIE
公开号:EP0356323A1
公开(公告)日:1990-02-28
Nouveaux dérivés de benzopyrrolidinone, utilisables comme médicament, et répondant à la formule :
dans laquelle :
- soit : R₁ et R₂ représentent ensemble avec la liaison de l'hétérocycle auquel ils sont attachés un noyau benzénique éventuellement substitué et simultanément R₃ et R₄ sont hydrogène, (C₁-C₄) alcoyle ou (C₅-C₆) cycloalcoyle ;
soit : R₁ est hydrogène, R₄ une liaison simple et R₂, R₃ représentent ensemble avec la liaison de l'hétérocycle auquel ils sont attachés un noyau benzénique éventuellement substitué ;
et
- A est une chaîne hydrocarbonée droite ou ramifiée de C₂ à C₆, éventuellement substituée par un hydroxy ;
- X est une liaison simple, oxygène ou soufre ; et
- Y est hydrogène, halogène ou (C₁-C₅) alcoyle ou alcoxy.
Ces nouveaux dérivés et leurs sels physiologiquement tolérables peuvent être utilisés en thérapeutique notamment dans le traitement des maladies bronchospastiques et des inflammations de la sphère O R L.
可用作药物的新型苯并吡咯烷酮衍生物,其式为:
其中:
- 或者R₁ 和 R₂ 与它们所连接的杂环的键一起代表一个任选取代的苯环,同时 R₃ 和 R₄ 是氢、(C₁-C₄)烷基或 (C₅-C₆)环烷基;
或R₁ 是氢,R₄ 是单键,R₂、R₃ 与它们所连接的杂环的键一起代表一个任选取代的苯环;
且
- A 是 C₂ 至 C₆ 的直链或支链烃链,可选择被羟基取代;
- X 是单键、氧或硫;以及
- Y 是氢、卤素或 (C₁-C₅) 烷基或烷氧基。
这些新衍生物及其生理上可耐受的盐类可用于治疗,特别是支气管痉挛性疾病和 O R L 球炎症的治疗。
p-TSA.H2O mediated one-pot, multi-component synthesis of isatin derived imidazoles as dual-purpose drugs against inflammation and cancer
作者:M. Rajesh Kumar、V. Violet Dhayabaran、N. Sudhapriya、A. Manikandan、Daniel A. Gideon、S. Annapoorani
DOI:10.1016/j.bioorg.2020.104046
日期:2020.9
A novel one-pot multicomponent reaction was performed to synthesize different imidazole and benzotriazole (BTA) isatin-based medicinally important compounds using (p-TSA center dot H2O) as an economical and operative acid catalyst. The yield of the products was found to be up to a maximum of 92% when using this catalyst. Antioxidant, anti-breast cancer and anti-inflammatory activities of these 13 isatin-based derivatives (named as 5a-m) were assessed. The inhibitory effects of these compounds were tested in vitro against cyclooxygenase-2 (COX-2, an enzyme responsible for inflammation) and phosphoinositide-3 kinase (PI3K, a key enzyme in breast cancer). "Among the 13 isatin-based Imidazole derivatives, five compounds (5a, 5d, 5f, 5 k and 5l) were found to exhibit anti-inflammatory as well as anti-cancer activity, which was validated using HRBC stabilization assay (to show anti-inflammatory activity) and cytotoxicity in MCF-7 (breast cancer cell line) to provide proof for anticancer property of the compounds". The molecular interactions between the two enzymes were probed using molecular docking. Structure-Activity Relationship (SAR) and ADMET prediction results were also useful to screen the most effective imidazole derivatives and to establish them as putative COX-2 inhibitors/anti-inflammatory drugs. These selected compounds which showed appreciable activity against COX-2 and PI3K are promising drug candidates for the treatment of breast cancer and inflammation which is often associated with breast cancer pathophysiology.
NEW SUBSTITUTED SPIROÝCYCLOALKYL-1,3'-INDOL¨-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS.
申请人:Almirall, S.A.
公开号:EP2280943A1
公开(公告)日:2011-02-09
US4968705A
申请人:——
公开号:US4968705A
公开(公告)日:1990-11-06
[EN] NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS.<br/>[FR] NOUVEAUX DÉRIVÉS SUBSTITUÉS DE SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA KINASE ACTIVÉE PAR LE MITOGÈNE P38
申请人:ALMIRALL SA
公开号:WO2009124692A1
公开(公告)日:2009-10-15
This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.